Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension
Number of Studies Evaluating Various Treatment Options
The 110 included direct comparator articles reported on 100 distinct studies. Seventy-four of these were randomized controlled trials (RCTs), 4 were nonrandomized controlled trials, 16 were retrospective cohort studies, 3 were prospective cohort studies, and 1 study each were a cross-sectional cohort, a case-control study, and a retrospective chart review. This table describes the number of studies that evaluated various possible treatment comparisons. As this table illustrates, enalapril was by far the most frequently studied ACEI (30 studies) and losartan the most frequently studied ARB, followed by telmisartan. The most commonly studied treatment comparison was the generic “ACEIs” versus “ARBs” (20 studies), followed by enalapril versus losartan (13 studies). Other treatment comparisons were fairly sparsely represented. Only three studies compared the DRI aliskiren with either an ACEI (ramipril) or ARB (losartan).
- Sanders GD, Coeytaux R, Dolor RJ, et al. Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Comparative Effectiveness Review No. 34. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 11-EHC063-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2011. Available at: http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=696.
Your slide tray is being processed.